Logo image of AGIO

AGIOS PHARMACEUTICALS INC (AGIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AGIO - US00847X1046 - Common Stock

26.49 USD
+1.25 (+4.95%)
Last: 11/24/2025, 4:30:00 PM
26.49 USD
0 (0%)
After Hours: 11/24/2025, 4:30:00 PM
Fundamental Rating

4

Overall AGIO gets a fundamental rating of 4 out of 10. We evaluated AGIO against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AGIO as it has an excellent financial health rating, but there are worries on the profitability. AGIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AGIO has reported negative net income.
In the past year AGIO has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: AGIO reported negative net income in multiple years.
In the past 5 years AGIO always reported negative operating cash flow.
AGIO Yearly Net Income VS EBIT VS OCF VS FCFAGIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

AGIO's Return On Assets of -28.96% is fine compared to the rest of the industry. AGIO outperforms 68.29% of its industry peers.
AGIO's Return On Equity of -31.24% is fine compared to the rest of the industry. AGIO outperforms 76.74% of its industry peers.
Industry RankSector Rank
ROA -28.96%
ROE -31.24%
ROIC N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
AGIO Yearly ROA, ROE, ROICAGIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

Looking at the Gross Margin, with a value of 87.22%, AGIO belongs to the top of the industry, outperforming 88.93% of the companies in the same industry.
AGIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGIO Yearly Profit, Operating, Gross MarginsAGIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

9

2. Health

2.1 Basic Checks

AGIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGIO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AGIO has less shares outstanding
AGIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AGIO Yearly Shares OutstandingAGIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AGIO Yearly Total Debt VS Total AssetsAGIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 7.95 indicates that AGIO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.95, AGIO belongs to the top of the industry, outperforming 80.30% of the companies in the same industry.
There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.95
ROIC/WACCN/A
WACC8.7%
AGIO Yearly LT Debt VS Equity VS FCFAGIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

AGIO has a Current Ratio of 13.82. This indicates that AGIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AGIO (13.82) is better than 90.06% of its industry peers.
AGIO has a Quick Ratio of 13.39. This indicates that AGIO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AGIO (13.39) is better than 89.49% of its industry peers.
Industry RankSector Rank
Current Ratio 13.82
Quick Ratio 13.39
AGIO Yearly Current Assets VS Current LiabilitesAGIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.92% over the past year.
Measured over the past years, AGIO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.03% on average per year.
Looking at the last year, AGIO shows a very strong growth in Revenue. The Revenue has grown by 36.26%.
EPS 1Y (TTM)7.92%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)36.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%43.69%

3.2 Future

The Earnings Per Share is expected to grow by 12.12% on average over the next years. This is quite good.
The Revenue is expected to grow by 92.72% on average over the next years. This is a very strong growth
EPS Next Y-6.2%
EPS Next 2Y-2.4%
EPS Next 3Y5.49%
EPS Next 5Y12.12%
Revenue Next Year27.91%
Revenue Next 2Y79.98%
Revenue Next 3Y98.74%
Revenue Next 5Y92.72%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
AGIO Yearly Revenue VS EstimatesAGIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
AGIO Yearly EPS VS EstimatesAGIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGIO. In the last year negative earnings were reported.
Also next year AGIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGIO Price Earnings VS Forward Price EarningsAGIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGIO Per share dataAGIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.4%
EPS Next 3Y5.49%

More info and screens

0

5. Dividend

5.1 Amount

AGIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGIOS PHARMACEUTICALS INC

NASDAQ:AGIO (11/24/2025, 4:30:00 PM)

After market: 26.49 0 (0%)

26.49

+1.25 (+4.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-11 2026-02-11/amc
Inst Owners108.68%
Inst Owner Change6.73%
Ins Owners0.87%
Ins Owner Change0.86%
Market Cap1.54B
Revenue(TTM)44.79M
Net Income(TTM)-401.26M
Analysts78.57
Price Target50.39 (90.22%)
Short Float %8.35%
Short Ratio7.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.7%
Min EPS beat(2)-4.68%
Max EPS beat(2)8.09%
EPS beat(4)3
Avg EPS beat(4)8.67%
Min EPS beat(4)-4.68%
Max EPS beat(4)16.46%
EPS beat(8)4
Avg EPS beat(8)-33.93%
EPS beat(12)8
Avg EPS beat(12)-8.73%
EPS beat(16)11
Avg EPS beat(16)-4.83%
Revenue beat(2)2
Avg Revenue beat(2)25.02%
Min Revenue beat(2)21.22%
Max Revenue beat(2)28.81%
Revenue beat(4)3
Avg Revenue beat(4)12.89%
Min Revenue beat(4)-11.26%
Max Revenue beat(4)28.81%
Revenue beat(8)3
Avg Revenue beat(8)2.38%
Revenue beat(12)5
Avg Revenue beat(12)1.3%
Revenue beat(16)6
Avg Revenue beat(16)-3.93%
PT rev (1m)1.65%
PT rev (3m)-0.8%
EPS NQ rev (1m)2.13%
EPS NQ rev (3m)1.39%
EPS NY rev (1m)1.6%
EPS NY rev (3m)1.42%
Revenue NQ rev (1m)-3.31%
Revenue NQ rev (3m)-12.94%
Revenue NY rev (1m)1.48%
Revenue NY rev (3m)-2.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.36
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-6.7
EYN/A
EPS(NY)-7.34
Fwd EYN/A
FCF(TTM)-7.13
FCFYN/A
OCF(TTM)-7.06
OCFYN/A
SpS0.77
BVpS22.11
TBVpS22.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.96%
ROE -31.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.22%
FCFM N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.87%
Cap/Sales 9.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.82
Quick Ratio 13.39
Altman-Z 7.95
F-Score3
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)33.97%
Cap/Depr(5y)62.68%
Cap/Sales(3y)14.2%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.92%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y-6.2%
EPS Next 2Y-2.4%
EPS Next 3Y5.49%
EPS Next 5Y12.12%
Revenue 1Y (TTM)36.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%43.69%
Revenue Next Year27.91%
Revenue Next 2Y79.98%
Revenue Next 3Y98.74%
Revenue Next 5Y92.72%
EBIT growth 1Y-16.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.55%
EBIT Next 3Y6.42%
EBIT Next 5YN/A
FCF growth 1Y-42.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.45%
OCF growth 3YN/A
OCF growth 5YN/A

AGIOS PHARMACEUTICALS INC / AGIO FAQ

What is the ChartMill fundamental rating of AGIOS PHARMACEUTICALS INC (AGIO) stock?

ChartMill assigns a fundamental rating of 4 / 10 to AGIO.


What is the valuation status for AGIO stock?

ChartMill assigns a valuation rating of 0 / 10 to AGIOS PHARMACEUTICALS INC (AGIO). This can be considered as Overvalued.


Can you provide the profitability details for AGIOS PHARMACEUTICALS INC?

AGIOS PHARMACEUTICALS INC (AGIO) has a profitability rating of 2 / 10.